Pegunigalsidase Alfa

2 trials 1 recruiting Orphan designation

Filter these 2 trials by condition, phase, country and more.

Open in Search →

2 Registered trials

1 Recruiting

1 Completed trials

1 Sponsors

8 Countries

Phase III

Phase II/III

Phase III: 1 Phase II/III: 1

Indications tested

Fabry´s disease 2

Sponsors using this IMP

Chiesi Farmaceutici S.p.A. 2

All trials

2 total

A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents with Fabry Disease Recruiting

2022-503128-29-00 Phase II/III 4 countries Chiesi Farmaceutici S.p.A.
Safety and Efficacy study assessing Pegunigalsidase Alfa (PRX-102) Administered by Intravenous Infusion Every 4 Weeks in Patients With Fabry… Ended

2024-516735-27-00 Phase III 5 countries Chiesi Farmaceutici S.p.A.

Showing 1–2 of 2 trials

← All drugs A–Z